Abstract On May 3, 2008, a National Cancer Institute (NCI)-sponsored open consensus
conference was held in Toronto, Ontario, Canada, during the 2008 International Society for …

An imaging biomarker that would provide for an early quantitative metric of clinical treatment
response in cancer patients would provide for a paradigm shift in cancer care. Currently …

Diffusion‐weighted MRI (DWI) allows the detection of malignancies in the abdomen and
pelvis. Lesion detection and characterization using DWI largely depends on the increased …

Diffusion-weighted magnetic resonance imaging (DWI) is increasingly being used to assess
tumour response to a variety of anticancer treatments. The technique is quick to perform …

Imaging biomarkers for the predictive assessment of treatment response in patients with
cancer earlier than standard tumor volumetric metrics would provide new opportunities to …

Diffusion-weighted (DW) magnetic resonance (MR) imaging is emerging as a powerful
clinical tool for directing the care of patients with cancer. Whole-body DW imaging is almost …

Assessment of the effectiveness of cancer therapy traditionally relies on comparison of tumor
images acquired before and after therapeutic intervention by inspection of gross anatomical …

The use of anatomical imaging in clinical oncology practice traditionally relies on
comparison of patient scans acquired before and following completion of therapeutic …

Background: A surrogate marker for treatment response that can be observed earlier than
comparison of sequential magnetic resonance imaging (MRI) scans, which depends on …

Following its success in early detection of cerebral ischemia, diffusion‐weighted imaging
(DWI) has been increasingly used in cancer diagnosis and treatment evaluation. These …